AI-driven pipeline Leverage Invea Therapeutics’ AI and ML driven approach to identify collaboration or licensing opportunities with CROs, biotech firms, or pharma companies seeking advanced computational methods to accelerate IMID drug discovery and preclinical optimization.

Oral small molecules Target partnerships around INVA8001 and INVA8003 as potential best-in-class oral therapies for immune-mediated inflammatory diseases like atopic dermatitis and chronic urticaria, appealing to companies with unmet needs in patient-friendly administration and disease control.

Chymase inhibitor focus Position as a specialist in mast cell–driven pathways with a chymase inhibitor, opening conversations with companies exploring complementary mechanisms or combination regimens to mitigate inflammation, epithelial damage, and fibrosis.

Phase milestones Monitor near-term progression into Phase 2b for INVA8001 to align business development activity with potential co-development, milestone financing, or strategic licensing discussions as clinical data emerges.

Gait to commercialization Capitalize on a small team footprint to emphasize agility in partnerships, offering flexible collaboration structures (milestone-based licenses, collaborations in GI/hepatobiliary areas) with faster decision cycles for potential acquirers or investors seeking nimble biotech assets.